|
Preface |
6 |
|
|
Contributors |
7 |
|
|
Contents |
10 |
|
|
to 1 Nicotine, Tobacco Use, and the 55th Nebraska Symposium on Motivation |
12 |
|
|
to 2 Synaptic Plasticity Within Midbrain Dopamine Centers Contributes to Nicotine Addiction |
15 |
|
|
Introduction to the Health Problem |
15 |
|
|
Midbrain Dopaminergic Systems |
16 |
|
|
Action of Nicotine at Nicotinic Receptors in the Midbrain |
17 |
|
|
Nicotine Influences Over Midbrain Synaptic Function |
19 |
|
|
to 3 Molecular Mechanisms Underlying the Motivational Effects of Nicotine |
26 |
|
|
Introduction |
26 |
|
|
Cues and Nicotine Dependence |
26 |
|
|
Prior Chronic Nicotine Exposure Enhances Conditioned Reinforcement |
27 |
|
|
Desensitization of nAChRs May Underlie the Ability of Nicotine to Enhance Cue Salience |
28 |
|
|
Brain Areas Important for Nicotine's Effects on Cue Responding |
29 |
|
|
Role of DA in Nicotine-Mediated Behaviors |
30 |
|
|
nAChR Subtypes Involved in Modulating the DA System |
31 |
|
|
Intracellular Signaling Downstream of nAChRs |
32 |
|
|
Conclusions |
33 |
|
|
to 4 Targeting Reward-Relevant Nicotinic Receptors in the Discovery of Novel Pharmacotherapeutic Agents to Treat Tobacco Dependence |
40 |
|
|
Introduction |
40 |
|
|
Tobacco Alkaloids and Tobacco Use |
40 |
|
|
Nicotinic Receptor-Mediated Dopamine Release in Nicotine Reward |
40 |
|
|
Nicotinic Receptor Subtypes |
42 |
|
|
nAChR Antagonists |
44 |
|
|
Approved Smoking Cessation Pharmacotherapies |
44 |
|
|
Novel nAChR Antagonists |
45 |
|
|
Methods |
47 |
|
|
Animals |
47 |
|
|
Synthesis of Analogs |
47 |
|
|
[ 3 H]DA Release Assay |
48 |
|
|
Nicotine-Induced Reinstatement of Nicotine Self-Administration |
49 |
|
|
Results and Discussion |
50 |
|
|
[ 3 H]DA Release Assay |
50 |
|
|
Nicotine-Induced Reinstatement of Nicotine Self-Administration |
58 |
|
|
to 5 Multiple Motivational Forces Contribute to Nicotine Dependence |
73 |
|
|
Introduction |
73 |
|
|
Rewarding Effects of Nicotine |
74 |
|
|
Primary Rewarding Effects of Nicotine |
74 |
|
|
Conditioned Rewarding Effects of Stimuli Associated with Nicotine Administration |
76 |
|
|
Reward-Enhancing Effects of Nicotine |
78 |
|
|
Primary Reward-Enhancing Effects of Nicotine |
78 |
|
|
Conditioned Reward-Enhancing Effects of Psychomotor Stimulants |
79 |
|
|
Nicotine Withdrawal |
81 |
|
|
Decreased Brain Reward Function during Nicotine Withdrawal |
81 |
|
|
The Somatic Aspects of Nicotine Withdrawal |
83 |
|
|
Motivational Significance of Anhedonic Versus Somatic Components of Drug Withdrawal |
83 |
|
|
Conditioned Nicotine Withdrawal |
85 |
|
|
Cognitive-Enhancing Effects of Nicotine |
90 |
|
|
Conclusions |
91 |
|
|
to 6 The Role of Nicotine in Smoking: A Dual-Reinforcement Model |
98 |
|
|
Introduction |
98 |
|
|
Role of Non-Nicotine Stimuli in Self-Administration and Smoking |
99 |
|
|
Dual Reinforcing Effects of Nicotine |
102 |
|
|
Predictions of the Dual-Reinforcement Model: Reinforcing Strength of the Nonpharmacological Stimulus |
103 |
|
|
Predictions of the Dual-Reinforcement Model: Behavioral Dissociation |
104 |
|
|
Predictions of the Dual-Reinforcement Model: Pharmacological Dissociation |
107 |
|
|
Predictions of the Dual-Reinforcement Model: Role of Conditioning |
108 |
|
|
Nature and Temporal Dynamics of Nicotine's Reinforcement-Enhancing Effects |
110 |
|
|
Significance of the Dual-Reinforcement Model |
111 |
|
|
Summary and Conclusions |
112 |
|
|
to 7 Altering the Motivational Function of Nicotine through Conditioning Processes |
117 |
|
|
Introduction |
117 |
|
|
Nicotine as a Reinforcer |
118 |
|
|
Nicotine as a Discriminative Stimulus |
121 |
|
|
Interoceptive Pavlovian Conditioning: A Historical Framework |
123 |
|
|
Nicotine as an Interoceptive CS |
124 |
|
|
Nicotine as an Interoceptive Occasion Setter |
128 |
|
|
Implications for the Motivational Function of Nicotine |
130 |
|
|
to 8 New Findings on Nicotine Addiction and Treatment |
136 |
|
|
Introduction |
136 |
|
|
Pre-cessation Administration of Pharmacologic Agents |
136 |
|
|
Pre-cessation use of Nicotine Replacement Therapy |
136 |
|
|
Varenicline |
140 |
|
|
Pre-cessation Mecamylamine Treatment |
141 |
|
|
Pre-cessation Bupropion Treatment |
141 |
|
|
Nicotine Vaccine |
141 |
|
|
Tailoring Smoking Cessation Treatment Based on Genetics |
143 |
|
|
Conclusion |
143 |
|
|
Financial Disclosure |
144 |
|
|
to 9 Sex Differences in Nicotine Reinforcement and Reward: Influences on the Persistence of Tobacco Smoking |
147 |
|
|
Introduction |
147 |
|
|
Clinical Implications of Sex Differences in Factors Promoting Smoking Persistence |
148 |
|
|
Possible Sources of Sex Differences in Smoking Reinforcement |
149 |
|
|
Pharmacokinetic |
149 |
|
|
Pharmacodynamic |
150 |
|
|
Non-pharmacological |
150 |
|
|
Gender |
151 |
|
|
Reduced Sensitivity to Nicotine Reinforcement and Reward in Women Versus Men |
151 |
|
|
Direct Effects of Nicotine on Self-administration Behavior and Reward Ratings |
152 |
|
|
Ad Lib Self-administration of Nicotine Nasal Spray |
152 |
|
|
Nicotine Versus Placebo Spray Choice |
153 |
|
|
Reinforcing and Rewarding Effects of Nicotine Dose via Cigarettes |
154 |
|
|
Influence of Nicotine Pre-treatment on Subsequent Nicotine or Smoking Reinforcement |
154 |
|
|
Ad lib Smoking Following Nicotine Spray Pre-treatment |
156 |
|
|
Nicotines Spray Choice Following Nicotine Patch Pre-treatment |
156 |
|
|
Other Relevant Findings |
157 |
|
|
Sex Differences in Non-Pharmacological Influences of Smoking |
157 |
|
|
Sex Differences in Sensitivity to Nonverbal Drug Information (Cues) |
158 |
|
|
Smoking Reinforcement due to Lit Cigarette Cue |
158 |
|
|
Smoking Reward and Reinforcement after Blocking Smoking Cues |
159 |
|
|
Sex Differences in Sensitivity to Verbal Drug Information (Expectancies) |
159 |
|
|
Sex Differences in the Reinforcing Effects of Control over Smoking |
162 |
|
|
Other Relevant Findings |
164 |
|
|
Clinical Implications |
165 |
|
|
Sex Differences in NRT Efficacy |
165 |
|
|
Sex Differences in Response to Other Medications |
167 |
|
|
Sex Differences in Treatments Aimed at Non-Nicotine Influences on Smoking |
167 |
|
|
Conclusions and Future Directions |
168 |
|
|
to 10 The Functional Significance of Craving in Nicotine Dependence |
174 |
|
|
Introduction |
174 |
|
|
Conventional Craving Assumptions |
175 |
|
|
How Do We Study Craving? |
176 |
|
|
Craving Assessment |
176 |
|
|
Factors that Affect Cigarette Craving |
177 |
|
|
Cigarette Abstinence |
177 |
|
|
Time of Day |
178 |
|
|
Alcohol Intoxication |
179 |
|
|
Stress and Negative Affect |
179 |
|
|
Smoking-Related Cues |
179 |
|
|
Cigarette Availability and Craving |
181 |
|
|
Tonic -- Phasic Distinction in Cigarette Craving |
183 |
|
|
Craving and Drug Use |
183 |
|
|
Addressing the Craving-- Drug Use Conundrum |
184 |
|
|
If Craving and Smoking Are Not Tightly Coupled, Why Study Craving? |
188 |
|
|
Ubiquity of Craving Among Smokers |
188 |
|
|
Prominence of Craving Among Abstinent Smokers |
188 |
|
|
Aversive Nature of Craving |
189 |
|
|
Craving as a Predictor of Relapse |
190 |
|
|
Craving as a Core Attribute of Nicotine Dependence |
190 |
|
|
Future of Craving Research |
192 |
|
|
Final Note |
194 |
|
|
to 11 The Motivational Impact of Nicotine and Its Role in Tobacco Use: Final Comments and Priorities |
201 |
|
|
Some Final Comments |
201 |
|
|
Future Priorities: The NIH Perspective |
203 |
|
|
Long-Term Surveys of Tobacco Use |
203 |
|
|
Genetics/Epigenetics |
204 |
|
|
Nicotine Vaccine |
204 |
|
|
Drug Exposure and Development |
204 |
|
|
Co-morbidity |
205 |
|
|
Neurobiological Substrates of Behavior |
205 |
|
|
National Cooperative Drug Discovery Group (NCDDG) |
205 |
|
|
Index |
1 |
|